A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T greater than 5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)
This Study is
No Longer Enrolling
Details
Age
Adult
Type of Study
Treatment
Scope
National
Locations
Rocky Mountain Regional VA Medical Center
Study ID
Protocol Number: 19-3018
More information available at ClinicalTrials.gov: NCT03447769
Categories
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers